Here's some potentially excellent news for your Friday. Following the Ebola scare of the past year, it appears one company could be close to a vaccine for the deadly virus.

Bloomberg News is reporting Merck & Co.’s vaccine for Ebola is “highly effective.” That's according to an interim analysis from a panel of experts who recommended that a late-stage trial should continue:

The vaccine was 100 percent effective when it was tested on more than 4,000 people who were in close contact with Ebola patients in the African nation of Guinea, the World Health Organization said, citing a study published today in the Lancet medical journal. The trial of the vaccine, called Ebola ca suffit -- “Ebola, that’s enough” in French -- began on March 23.

Ebola has killed more than 11,000 people in West Africa following an outbreak at the end of 2013. A few cases were diagnosed here in the U.S. as well.

In the study, people were protected against the Ebola virus within six to 10 days of vaccination. .